Connect with Us on Twitter
Learn about the Kidney Institute's news and current events.
@KUJGKI on TwitterThe Jared Grantham Kidney Institute is a world-class, internationally recognized research center. Our mission is to support basic, clinical and translational research leading to major advances in the prevention and treatment of kidney diseases. The Kidney Institute is committed to the pursuit of excellence by creating an environment that empowers creativity and innovation and encourages collaboration and teamwork between laboratory scientists and physicians.
As one of the top kidney research centers in the country, the Kidney Institute gives hope to those with kidney disease. Our research teams identify risk factors that affect the progression of kidney disease and we develop improved treatments.
News & Highlights
1/24/2023
PKD Summer Research Stipends
The University of Kansas PKD Center in the Jared Grantham Kidney Institute is accepting applications for a limited number of summer research internships for undergraduate and graduate students who are interested in working on a mentored research project related to polycystic kidney disease. Applications Due 2/28/2023
12/1/2022
Our KU Polycystic Kidney Disease care team is proud of receiving designation as a Center of Excellence from the PKD Foundation. The award will fund navigator services for polycystic kidney disease patients. Our PKD team is dedicated to patient-focused, comprehensive care & research discovery.
View the November 2022 Newsletter
10/7/2022
Robin Maser's research team identifies mechanism for critical function of a damaged protein that causes most polycystic kidney disease
10/6/2022
Congratulations to James Calvet and team for being featured by the American Journal of Physiology as the October APSSelect article, "The lonidamine derivative H2-gamendazole reduces cyst formation in polycystic kidney disease"
Read the article in American Journal of Physiology-Renal
9/18/2022
Exciting findings by JGKI researchers Darren Wallace, Stephen Parnell and team show that B-RAF activation alone can induce kidney cysts and exacerbate polycystic kidney disease in mouse models.
Read the article in Kidney International
9/7/2022
JGKI faculty Mei Liu and Alan Yu talk about using artificial intelligence prediction models for acute kidney injury on Open Mic with Dr. Stites.
FDA approves the first treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
The U.S. Food and Drug Administration (FDA) approved JYNARQUE TM (Tolvaptan), an arginine vasopressin (AVP) V2 receptor antagonist, as the first therapeutic treatment for patients with ADPKD in the United States. The concept for the use of AVP V2 receptor blockers to treat ADPKD originated from basic research performed in the Jared Grantham Kidney Institute at the University of Kansas Medical Center, which owns the use patent. And critical to the development of JYNARQUE TM were clinical trials carried out by KUMC Kidney Institute clinical investigators.
Related Links
Conferences & Seminars
- Salt & Water Conference - Tuesdays from noon - 1 p.m.
Grantham Conference Room, 6016 Wahl Hall East - Sullivan Conference - Fridays from 8:30 - 9:30 a.m.
Grantham Conference Room, 6016 Wahl Hall East